Rocket Pharmaceuticals CEO Gaurav Shah sells $9,591 in company stock

CEO of Rocket Pharmaceuticals, Gaurav Shah, sold 2,837 shares of the company’s common stock on August 13, 2026, for a total of $9,591, according to a regulatory filing. Each share was sold at $3.381, close to the stock’s 52-week low of $2.53. The sale was primarily to satisfy tax obligations related to the vesting of Restricted Stock Units (RSUs).

After the transaction, Mr. Shah still directly owns 1,058,887 shares of Rocket Pharmaceuticals, including RSUs that convert to common stock, while 207,897 shares are held indirectly by his spouse, and 198,341 shares are held by the Gaurav D. Shah Irrevocable Trust. Despite the sale, Rocket Pharmaceuticals remains financially strong with a current ratio of 9.24 and more cash than debt, though the company is rapidly depleting its cash reserves.

The company recently sold its Rare Pediatric Disease Priority Review Voucher for $180 million, following the FDA's approval of KRESLADI, a gene therapy. At the 2026 Annual Meeting of Stockholders, shareholders approved the election of seven new directors. TD Cowen maintains a Hold rating on the stock, noting the absence of safety events in initial Danon disease patients treated with RP-A501.